Skip to content

Released May 9, 2012, after the close

10-Q filed May 9, 2012, 39 days after period end · 0001144204-12-027198

Q1 2012 · 10-Q
Revenue$3.86Mno prior Q1 2011 on file+63.5% vs Q4 2011
Net Income-$5.90MN/M vs Q1 2011N/M vs Q4 2011
EPS Diluted$0.07+16.7% vs Q1 2011no prior Q4 2011 on file
Gross Profit$2,408,000—
Operating Income-$6,065,000—
Operating Cash Flow-$6,281,000N/M
Free Cash Flowderived-$7,091,000N/M
Margins · derived
Gross margin62.4%
Operating margin-157.1%
Net margin-152.9%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2012Q1 2011
Revenue$3.86M—
Net Income-$5.90M-$5.05M
EPS Diluted$0.07$0.06

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR